FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to polymorph of mesylate salt of 2-(5-(4-(2-morpholinethoxy)phenyl)pyridine-2-yl)-N-benzylacetamide, possessing properties of Syk inhibitor, method of its synthesis, based on it pharmaceutical composition and its application for treatment and prevention of cell proliferation.
EFFECT: obtaining composition, possessing properties of Syk inhibitor.
17 cl, 10 tbl, 28 dwg, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID FORMS OF 2-(5-(4-(2-MORPHOLINOETHOXY)PHENYL)PYRIDINE-2-IL)-N-BENZYLACETAMIDE | 2018 |
|
RU2802964C2 |
| SALTS AND POLYMORPHS OF SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE | 2015 |
|
RU2732125C2 |
| METHODS OF PRODUCTION ISOQUINOLINONES AND SOLID FORMS ISOQUINOLINONES | 2012 |
|
RU2626883C2 |
| SOLID FORMS OF (1,1-DIOXO-4-THIOMORPHOLINYL) - [6 - [[3- (4-FLUOROPHENYL) -5-METHYL-4-ISOXAZOLYL] METHOXY] -3-PYRIDINYL] METHANONE | 2012 |
|
RU2618524C2 |
| VARIOUS FORMS OF 6-CHLORO-2-ETHYL-N-(4-(4-(4-(TRIFLUOROMETHOXY)PHENYL)PIPERIDIN-1-YL)BENZYL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE | 2019 |
|
RU2826176C2 |
| PHARMACEUTICAL COMPOUNDS | 2020 |
|
RU2826182C1 |
| 3-[1,2,3,6-TETRAHYDROPYRIDIN-2-YL]PYRIDINE GLUTARATE OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF | 2019 |
|
RU2823979C2 |
| NEW CRYSTALLINE SALT FORM OF 2,2-DIMETHYL-6-((4-((3,4,5-TRIMETHOXYPHENYL)AMINO)-1,3,5-TRIAZIN-2-YL)AMINO)-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE FOR MEDICAL USE | 2016 |
|
RU2621187C1 |
| SOLID FORMS | 2007 |
|
RU2496780C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2387653C2 |
